185 related articles for article (PubMed ID: 33809486)
1. The Five-Year Prospective Study of Quality of Life in Hemifacial Spasm Treated with Abo-Botulinum Toxin A.
Kongsaengdao S; Maneeton N; Maneeton B
Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33809486
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
3. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
Xiao L; Pan Y; Zhang X; Hu Y; Cai L; Nie Z; Pan L; Li B; He Y; Jin L
Neurol Sci; 2016 Nov; 37(11):1807-1813. PubMed ID: 27431279
[TBL] [Abstract][Full Text] [Related]
4. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of stigmatization in hemifacial spasm and quality of life before and after botulinum toxin treatment.
Yuksel B; Genc F; Yaman A; Goksu EO; Ak PD; Gomceli YB
Acta Neurol Belg; 2019 Mar; 119(1):55-60. PubMed ID: 30178181
[TBL] [Abstract][Full Text] [Related]
6. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Cakmur R; Ozturk V; Uzunel F; Donmez B; Idiman F
J Neurol; 2002 Jan; 249(1):64-8. PubMed ID: 11954870
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Wu CJ; Shen JH; Chen Y; Lian YJ
Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
[TBL] [Abstract][Full Text] [Related]
8. A Study on Clinical Profile of Hemifacial Spasm in India and the Therapeutic Response to Botulinum Toxin Type A Injection as well as Pre and Postinjection Quality of Life.
Misra AK; Mukherjee J; Kumar S; Guha G; Mohanty B; Ngullie PS; Manna A; Nanda T; Das AK; Tiwari K
J Assoc Physicians India; 2022 Dec; 70(12):11-12. PubMed ID: 37355970
[TBL] [Abstract][Full Text] [Related]
9. An investigation into quality of life improvement in patients undergoing microvascular decompression for hemifacial spasm.
Lawrence JD; Frederickson AM; Chang YF; Weiss PM; Gerszten PC; Sekula RF
J Neurosurg; 2018 Jan; 128(1):193-201. PubMed ID: 28186450
[TBL] [Abstract][Full Text] [Related]
10. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
[TBL] [Abstract][Full Text] [Related]
11. Subjective and Objective Measures in the Treatment of Hemifacial Spasm With OnabotulinumtoxinA.
Chundury RV; D'Angelo AS; Couch SM; Holds JB
Ophthalmic Plast Reconstr Surg; 2016; 32(2):133-7. PubMed ID: 25811161
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin A improves psychological distress in patients with hemifacial spasm.
Wang C; Zhu X; Xia L; Xie P; Tian X; Shang J; Han Q
Acta Neurol Belg; 2022 Feb; 122(1):43-49. PubMed ID: 33515182
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial.
Wickwar S; McBain H; Newman SP; Hirani SP; Hurt C; Dunlop N; Flood C; Ezra DG
Trials; 2016 Mar; 17(1):129. PubMed ID: 26961367
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years.
Sorgun MH; Yilmaz R; Akin YA; Mercan FN; Akbostanci MC
J Clin Neurosci; 2015 Aug; 22(8):1319-25. PubMed ID: 26100157
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
Defazio G; Abbruzzese G; Girlanda P; Vacca L; Currà A; De Salvia R; Marchese R; Raineri R; Roselli F; Livrea P; Berardelli A
Arch Neurol; 2002 Mar; 59(3):418-20. PubMed ID: 11890846
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting the quality of life in hemifacial spasm patients.
Rudzińska M; Wójcik M; Malec M; Grabska N; Szubiga M; Hartel M; Szczudlik A
Neurol Neurochir Pol; 2012; 46(2):121-9. PubMed ID: 22581593
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30).
Tan EK; Fook-Chong S; Lum SY; Lim E
J Neurol Sci; 2004 Apr; 219(1-2):151-5. PubMed ID: 15050451
[TBL] [Abstract][Full Text] [Related]
18. Differences in Corneal Parameters Between Affected and Normal Contralateral Eyes in Patients With Hemifacial Spasm Treated With Botulinum Toxin-A: Outcomes During One Complete Treatment Cycle.
Osaki T; Osaki MH; Osaki TH; Hirai FE; Campos M
Cornea; 2016 Feb; 35(2):220-5. PubMed ID: 26619386
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin.
Setthawatcharawanich S; Sathirapanya P; Limapichat K; Phabphal K
Qual Life Res; 2011 Nov; 20(9):1519-23. PubMed ID: 21431990
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
